The long-awaited results of a U.S. Phase Three clinical trial of Oxford-AstraZeneca's COVID-19 vaccine has shown a near 80 percent efficacy rate with no causal relationship to blood clots.
In a press release on Monday, AstraZeneca said its shot's effectiveness against symptomatic illness came in at 79 percent and 100 percent against severe disease and hospitalization.
More than 32-thousand people from the U.S., Chile and Peru had participated in the trial, either receiving two doses of the vaccine or a placebo vaccine at a four-week interval. It was run by experts at Columbia University and the University of Rochester.
AstraZeneca also said a specific review had found no link between its vaccine and blood clots or the rare cerebral venal sinus thrombosis(CVST).
The results were unveiled amid lingering suspicions over the efficacy and safety of the vaccine jointly developed by the British-Swedish pharmaceutical company and Oxford University.